TYRA vs. OCUL, AGIO, DNLI, GLPG, IDYA, SRPT, BLTE, HRMY, IRON, and MESO
Should you be buying Tyra Biosciences stock or one of its competitors? The main competitors of Tyra Biosciences include Ocular Therapeutix (OCUL), Agios Pharmaceuticals (AGIO), Denali Therapeutics (DNLI), Galapagos (GLPG), IDEAYA Biosciences (IDYA), Sarepta Therapeutics (SRPT), Belite Bio (BLTE), Harmony Biosciences (HRMY), Disc Medicine (IRON), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry.
Tyra Biosciences vs. Its Competitors
Ocular Therapeutix (NASDAQ:OCUL) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.
Tyra Biosciences has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -382.51%. Tyra Biosciences' return on equity of -31.22% beat Ocular Therapeutix's return on equity.
59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by insiders. Comparatively, 15.2% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Tyra Biosciences has lower revenue, but higher earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.
Ocular Therapeutix has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.
Ocular Therapeutix currently has a consensus price target of $17.20, indicating a potential upside of 37.38%. Tyra Biosciences has a consensus price target of $30.83, indicating a potential upside of 149.26%. Given Tyra Biosciences' higher probable upside, analysts plainly believe Tyra Biosciences is more favorable than Ocular Therapeutix.
In the previous week, Ocular Therapeutix had 5 more articles in the media than Tyra Biosciences. MarketBeat recorded 11 mentions for Ocular Therapeutix and 6 mentions for Tyra Biosciences. Ocular Therapeutix's average media sentiment score of 1.38 beat Tyra Biosciences' score of 0.20 indicating that Ocular Therapeutix is being referred to more favorably in the media.
Summary
Tyra Biosciences beats Ocular Therapeutix on 9 of the 14 factors compared between the two stocks.
Get Tyra Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TYRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tyra Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:TYRA) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access